surgery-anesthesia-euro-gastro-congress-2018-keynote

9 / 9

N o v e m b e r 1 2 - 1 3 , 2 0 1 8 | R o m e , I t a l y
Note:
Page 33
Surgery and Anesthesia 2018 & Euro Gastro Congress 2018 Case Reports in Surgery and Invasive Procedures| Volume 2
&
GASTROENTEROLOGY
3rd International Conference on
SURGERY AND ANESTHESIA
International Conference on
Joint Event on
OF EXCELLENCE
IN INTERNATIONAL
MEETINGS
YEARS
Iftikhar Ahmed, Case Rep Surg Invasive Proced 2018, Volume 2
VOLATILE ORGANIC METABOLITES AS
NOVEL, NON-INVASIVE DIAGNOSTIC
BIOMARKERS IN INFLAMMATORY BOWEL
DISEASE
T he diagnosis of inflammatory bowel disease (IBD) requires extensive and
often invasive investigations including colonoscopy and histology and
places a heavy burden, both on healthcare resources, because of the cost,
and on the individual, in times of disease-related disability and poor quality of
life. Recently, there has been increasing interest in non-invasive biomarkers to
diagnose IBD and to monitor the disease activity. There is growing scientific
interest in the investigation of volatile metabolites and numbers of studies
have focused on the utilization of non-invasive biomarkers in the diagnosis of
GI disease.
The development of sophisticated analytical techniques has enabled the
study and interpretation of changes in the faecal and breath volatile organic
metabolites (VOMs) and its correlation with the pathophysiological mecha-
nisms in IBD. VOMs are the chemicals that are the products and intermediates
of metabolism and may be altered during the diseases process. Changes in
the signature of VOMs could potentially provide diagnostic information about
health and disease. Multiple studies have reported the differences in VOM
profiles of healthy controls vs. patients with IBD other GI disorders. VOM pro-
files have been used to segregate patients by disease activity and the type of
disease. The correlation of VOMs with microbiota is interesting and supports
the hypothesis of gut microbial dysbiosis in the etiology of IBD. This provides
an important platform to explore the role of dysbiosis in IBD and other GI dis-
orders pathogenesis and development of novel therapeutic targets. In future,
further understanding of faecal VOMs may lead to the development of a rapid
and simple point of care diagnosis and monitoring of IBD.
Biography
Iftikhar Ahmed is a consultant gastroenterologist
at University Hospital Southampton NHS Founda-
tion Trust and visiting consultant at East Sussex
Healthcare NHS Trust, Eastbourne. He is also an
honourable senior clinical lecturer at the University
of Southampton UK. His research interests include
investigating the changes in the smell of faeces
and breathe in order to understand the pathophys-
iological mechanisms of GI disorders and to devel-
op a non-invasive biomarker. Through formal labo-
ratory research, Ahmed studied the faecal volatile
metabolomics profiles of patients with liver dis-
ease ( NAFLD), IBD and irritable bowel syndrome
(IBS) in comparison with healthy individuals, and
was awarded the degree of doctorate of medicine
(MD) by University of the Bristol in 2012.
Iftikhar Ahmed
Aldara Hospital and Medical Centre, UK